How to Fight Insurance Denials for Multiple Myeloma Treatment

Multiple myeloma is a cancer of plasma cells in the bone marrow, and over the past decade treatment has been transformed by waves of new drugs: anti-CD38 monoclonal antibodies (Darzalex, Sarclisa), immunomodulatory drugs (IMiDs like Revlimid and Pomalyst), proteasome inhibitors (Velcade, Kyprolis, Ninlaro), and most recently BCMA and GPRC5D bispecific T-cell engagers (Tecvayli, Elrexfio, Talvey, Lynozyfic). Autologous stem-cell transplant with high-dose melphalan remains standard for transplant-eligible patients, followed by long-term maintenance therapy. Despite these advances—and FDA approvals—insurers routinely deny coverage, citing "investigational" status, demanding more prior lines of therapy, requiring step-edits through older drugs, or rejecting subcutaneous formulations as not "medically necessary." This guide walks you through the most common denial templates, the clinical evidence and policy citations that carry weight, and step-by-step strategies to overturn each type of denial.

---

Why Insurers Deny Multiple Myeloma Treatment

1. "Investigational / Experimental" for BCMA or GPRC5D Bispecifics

Tecvayli (teclistamab), Elrexfio (elranatamab), Talvey (talquetamab), and Lynozyfic (linvoseltamab) all received FDA accelerated approval between October 2022 and July 2025 for relapsed/refractory multiple myeloma after ≥4 prior lines. Insurers nonetheless label them "experimental," particularly when prescribed earlier in the treatment sequence or in combination, ignoring the fact that accelerated approval is full legal marketing authorization and that National Comprehensive Cancer Network (NCCN) guidelines list these agents as category 1 or 2A preferred options for heavily pretreated disease.

2. Step-Therapy Mandates: "Must Fail Older, Cheaper Drugs First"

Plans often require documented progression on every permutation of IMiD + proteasome inhibitor + anti-CD38 before authorizing a bispecific or second-generation agent, even when the patient is already triple-class or penta-refractory. They may insist on trying Pomalyst before Tecvayli, or Ninlaro before Kyprolis, despite evidence that cycling through marginally differentiated drugs in a refractory patient delays effective therapy and risks rapid progression or end-organ damage.

3. Line-of-Therapy Counting Games

Insurers count induction + autologous transplant + maintenance as a single "line" to argue that a patient has received fewer prior regimens than the FDA label specifies, thereby denying access to later-line drugs. In reality, clinical trials and the International Myeloma Working Group (IMWG) count each distinct treatment phase, and progression on maintenance constitutes relapse requiring a new line.

4. Subcutaneous Formulation Denials: "IV Is Adequate"

Darzalex Faspro (daratumumab + hyaluronidase subcutaneous) was shown non-inferior to Darzalex IV in the COLUMBA trial (Mateos, Lancet Haematology 2020) and cuts infusion time from 6+ hours to ~5 minutes, dramatically reducing chair time, infusion reactions, and patient burden. Insurers routinely deny the subcutaneous formulation as "not medically necessary" or "convenience only," ignoring quality-of-life, safety, and health-system efficiency data.

5. Post-Transplant Maintenance Denials

Long-term Revlimid (lenalidomide) maintenance after autologous stem-cell transplant confers a ~25-month progression-free survival benefit in landmark trials (CALGB 100104, Myeloma XI). Nonetheless, insurers deny maintenance as "prophylactic" rather than "active treatment," set arbitrary duration caps (e.g., 2 years), or demand dose reductions below effective levels to control costs.

---

The Citations Insurers Respect

When you appeal, name the specific guidelines, trials, and policy statements verbatim. Insurers rely on medical directors who scan for recognized evidence hierarchies; vague references to "studies" carry no weight.

Guidelines and Consensus Statements

• NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma, version 3.2024

The definitive US treatment algorithm. NCCN category 1 = high-level evidence and uniform consensus; category 2A = lower-level evidence but uniform consensus that the intervention is appropriate. Bispecifics, anti-CD38 antibodies, and modern triplet/quadruplet induction regimens are all NCCN-listed.

• International Myeloma Working Group (IMWG) Consensus Criteria

Defines response (sCR, CR, VGPR, PR), progression, relapse, and refractoriness. Cite IMWG uniform response criteria (Kumar et al., Lancet Oncology 2016 update) to document triple-class or penta-refractory status and validate your treating oncologist's assessment.

• American Society of Clinical Oncology (ASCO) / American Society of Hematology (ASH) Guidelines

ASH publishes annual updates on myeloma management; ASCO periodically releases Clinical Practice Guidelines on supportive care and specific drug classes.

Pivotal Trials: Anti-CD38 Monoclonal Antibodies

• ALCYONE (Mateos et al., NEJM 2018): Darzalex + bortezomib/melphalan/prednisone (D-VMP) vs VMP in newly diagnosed transplant-ineligible MM; established daratumumab in the frontline setting.
• MAIA (Facon et al., NEJM 2019): Darzalex + lenalidomide/dexamethasone (DRd) vs Rd in transplant-ineligible NDMM; 5-year follow-up showed ongoing PFS benefit.
• COLUMBA (Mateos et al., Lancet Haematology 2020): Daratumumab subcutaneous (Faspro) non-inferior to IV, with lower infusion reactions and 5-minute administration.
• IMROZ (Facon et al., presented ASCO 2024, FDA approval September 20, 2024): Sarclisa (isatuximab) + VRd in newly diagnosed transplant-ineligible MM; confirmed frontline anti-CD38 benefit.
• ICARIA-MM (Attal et al., Lancet 2019): Sarclisa + pomalidomide/dexamethasone (IsaPd) vs Pd in relapsed/refractory MM (≥2 prior lines); FDA approval March 2, 2020.

Pivotal Trials: BCMA and GPRC5D Bispecific T-Cell Engagers

• MajesTEC-1 (Moreau et al., NEJM 2022): Tecvayli (teclistamab) in heavily pretreated RRMM (≥3 prior lines including anti-CD38, IMiD, PI); overall response rate 63%, median duration of response 18.4 months; FDA accelerated approval October 25, 2022.
• MagnetisMM-3: Elrexfio (elranatamab) pivotal study; FDA accelerated approval August 14, 2023 for ≥4 prior lines.
• MonumenTAL-1: Talvey (talquetamab), the first GPRC5D bispecific; ORR 73% at the 0.4 mg/kg dose; FDA accelerated approval August 9, 2023.
• LINKER-MM1: Lynozyfic (linvoseltamab) ORR 71.5% in ≥3 prior lines; FDA accelerated approval July 2, 2025.

Pivotal Trials: Proteasome Inhibitors and IMiDs

• SWOG S0777 (Durie et al., Lancet 2017): VRd (bortezomib/lenalidomide/dexamethasone) vs Rd induction pre-transplant; established VRd as standard triplet.
• FORTE (Gay et al., JCO 2021): Carfilzomib/lenalidomide/dexamethasone (KRd) vs KCd induction in transplant-eligible MM.
• TOURMALINE-MM1 (Moreau et al., NEJM 2016): Ixazomib/lenalidomide/dexamethasone (IRd) maintenance; oral proteasome inhibitor option.
• BOSTON (Grosicki et al., Lancet 2020): Selinexor (Xpovio) + bortezomib/dexamethasone (SVd) vs Vd in relapsed/refractory MM (1–3 prior lines); FDA approval expanded December 2020.

Pivotal Trials: Autologous Stem-Cell Transplant and Maintenance

• CALGB 100104 / ECOG (McCarthy et al., NEJM 2012; Lonial et al., Blood 2022 long-term follow-up): Lenalidomide maintenance post-auto-HSCT improved PFS and OS; median PFS benefit ~25 months.
• Myeloma XI (Jackson et al., Lancet Oncology 2019): UK trial confirming maintenance benefit and transplant benefit in NDMM.
• CASSIOPEIA (Moreau et al., Lancet 2019): Dara-VTd induction and post-transplant consolidation; higher MRD negativity.
• GRIFFIN (Voorhees et al., JCO 2020 and long-term updates): Dara-RVd induction + Dara-R maintenance in newly diagnosed transplant-eligible MM; ongoing phase II data support quadruplet induction.

---

How to Argue Against Each Major Denial Reason

1. Fighting "Investigational / Experimental" Denials for Bispecifics

Concrete steps:

1. Cite the exact FDA approval date and indication.

Example: "Tecvayli (teclistamab-cqyv) received FDA accelerated approval on October 25, 2022, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. This is full legal marketing authorization under 21 CFR 314 Subpart H, not an investigational new drug."

2. Attach the FDA prescribing information (package insert).

Download the current label from accessdata.fda.gov/scripts/cder/daf. Highlight the "Indications and Usage" section.

3. Reference the pivotal trial by name and journal.

"The indication is based on the MajesTEC-1 trial, published in the New England Journal of Medicine in August 2022 (Moreau et al., NEJM 2022;387:495–505), which demonstrated an overall response rate of 63% and a median duration of response of 18.4 months in heavily pretreated patients, including those triple-class refractory."

4. Cite NCCN category 2A listing.

"The NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma (v.3.2024) list teclistamab as a category 2A preferred regimen for relapsed/refractory disease after ≥4 prior lines. Under your plan's medical policy [cite policy number if available], NCCN category 2A recommendations constitute 'medically necessary' care."

5. Document triple-class or penta-refractory status per IMWG.

Provide a table: "Patient has documented progression on [list drugs and dates]. Per IMWG consensus criteria (Kumar et al., Lancet Oncology 2016), this constitutes triple-class refractory disease (anti-CD38 refractory: Darzalex; IMiD refractory: lenalidomide and pomalidomide; PI refractory: bortezomib). No remaining standard-of-care options exist prior to bispecific therapy."

6. Address CAR-T sequencing if applicable.

"While CAR-T therapies (Abecma, Carvykti) are FDA-approved for similar indications, patient is not an immediate candidate due to [manufacturing lead time >6 weeks / rapidly progressive disease / prior CAR-T failure / bridging therapy toxicity]. Bispecific antibodies offer immediate off-the-shelf administration and are recognized by NCCN as appropriate in this setting."

Key point: Accelerated approval is not "experimental." FDA accelerated approval pathway requires substantial evidence of effectiveness; the word "accelerated" refers to approval before completion of post-market confirmatory trials, not investigational status.

---

2. Overcoming Step-Therapy / Fail-First Mandates

Concrete steps:

1. Document refractoriness to each required drug class.

Create a table:

```

Line 1: VRd (bortezomib/lenalidomide/dex) 2023-01 to 2023-08 → progression (refractory to lenalidomide + bortezomib)

Line 2: DPd (Darzalex/pomalidomide/dex) 2023-09 to 2024-12 → progression (refractory to daratumumab + pomalidomide)

Triple-class refractory per IMWG: anti-CD38 (Darzalex), IMiD (lenalidomide, pomalidomide), PI (bortezomib)

```

2. Cite the FDA label's "≥4 prior lines" language and argue your count.

"FDA label for [drug] specifies ≥4 prior lines. Patient has received: (1) VRd induction, (2) auto-HSCT consolidation, (3) lenalidomide maintenance (progression = new line), (4) DPd salvage. This constitutes four distinct therapeutic interventions per IMWG and clinical trial convention."

3. Invoke medical necessity for triple-class refractory patients.

"Once a patient is refractory to all three major drug classes, NCCN guidelines (MM v.3.2024, page MS-33) recommend novel agents including bispecifics rather than recycling ineffective drugs. Requiring additional failed lines exposes the patient to disease progression, end-organ damage (renal failure, pathologic fracture, spinal cord compression), and potentially irreversible harm."

4. Cite state step-therapy override statutes if applicable.

Many states (e.g., California AB 2472, New York Insurance Law § 4903) allow override of step therapy when:

- The required step drug is contraindicated or likely to be ineffective based on known clinical characteristics.

- The patient has tried and failed the step drug in the same or a different line of therapy.

- The step drug causes or is likely to cause an adverse reaction or harm.

State: "Under [state] law, step-therapy protocols must be overridden when the patient has already failed the required medication or when delay would cause harm. Patient meets both criteria."

5. Request an expedited peer-to-peer review.

Ask your oncologist to speak directly with the insurer's medical director. Have your doctor prepare:

- Timeline of all prior regimens and responses

- Documentation of refractoriness (imaging, lab trends, IMWG progression criteria)

- Citation of pivotal trials and NCCN pathways

- Risk of delay (e.g., rising light chains, new lytic lesions, hypercalcemia, renal impairment)

---

3. Challenging Line-of-Therapy Counting

Concrete steps:

1. Use IMWG definitions of line of therapy.

From Kumar et al. (Lancet Oncology 2016) and clinical trial convention:

- A new line begins with any new anti-myeloma regimen after disease progression or relapse.

- Induction + transplant + maintenance is typically counted as one line if given in continuous sequence without intervening progression, but progression on maintenance starts a new line.

2. Provide a clear timeline.

Example letter language:

```

Line 1 (2023-01 to 2024-06):

- VRd induction ×4 cycles → PR

- Auto-HSCT with melphalan 200 conditioning 2023-09 → sCR

- Lenalidomide maintenance 10 mg daily starting 2023-12

- Biochemical relapse 2024-06 (rising M-spike, loss of CR)

Line 2 (2024-07 to 2025-03):

- DPd (Darzalex Faspro + pomalidomide + dex) → VGPR → progression 2025-03 (new lytic lesions, doubling of light chains)

Line 3 (requested):

- Tecvayli per MajesTEC-1 inclusion criteria (≥3 prior lines, triple-class refractory)

```

3. Cite the pivotal trial's inclusion criteria.

MajesTEC-1 enrolled patients with ≥3 prior lines; show that your line count matches the trial definition: "Patient enrolled in MajesTEC-1 had to have received prior PI, IMiD, and anti-CD38. Our patient meets this exactly. The trial did not require five or six lines; the FDA approval was based on this ≥3 (later updated to ≥4 in some contexts) standard."

4. Distinguish consolidation/maintenance from a new line.

"Auto-HSCT is a dose-intensification consolidation of the induction regimen, not a separate line. However, progression during or after maintenance therapy constitutes relapse and initiates a new line per IMWG uniform criteria."

---

4. Winning Coverage for Subcutaneous Formulations (Darzalex Faspro)

Concrete steps:

1. Cite the COLUMBA trial.

"Darzalex Faspro (daratumumab 1800 mg + hyaluronidase subcutaneous) was proven non-inferior to Darzalex IV in the COLUMBA trial (Mateos et al., Lancet Haematology 2020;7:e370–e380). The primary endpoint—overall response rate at week 24—was met, with ORR 41% for SC vs 37% for IV (difference +3.6%, 95% CI −5.2 to 12.3, within the prespecified 15% non-inferiority margin). Trough daratumumab levels were comparable."

2. Emphasize safety and tolerability.

"Systemic infusion-related reactions occurred in 13% of SC patients vs 34% of IV patients (p<0.001). The SC formulation reduced median administration time from 6–7 hours (first IV dose) to ~5 minutes, decreasing the risk of infusion reactions, chair-time exposure, and nursing resource utilization."

3. Quantify patient-specific factors favoring SC.

- Poor IV access or history of difficult peripheral/central venous catheterization

- Prior severe infusion reaction to IV daratumumab (even if premedicated)

- Frailty, comorbidities, or distance from infusion center making 6+ hour visits burdensome

- Active infection risk or immunosuppression making prolonged in-facility time hazardous (particularly relevant post-COVID)

4. Cite medical policy and FDA labeling parity.

"FDA approved Darzalex Faspro on May 1, 2020, with the same indications as IV daratumumab. The prescribing information states the SC formulation is indicated for all approved daratumumab regimens. Your medical policy [cite policy number] states that SC biologics are covered when shown non-inferior and offering clinical advantage. COLUMBA satisfies both."

5. Note cost-effectiveness from the payer perspective.

Studies (e.g., Gomes et al., Journal of Medical Economics 2021) show that while the drug acquisition cost is similar, total cost of care is lower for SC due to reduced infusion nursing time, fewer infusion reactions, and fewer dose delays. If your insurer's denial cites cost, rebut: "The chair time and nursing cost saved by SC administration offset any marginal drug cost difference and reduce emergency-department visits for infusion reactions."

---

5. Securing Post-Transplant Maintenance Therapy

Concrete steps:

1. Cite CALGB 100104 and Myeloma XI.

"Two phase III randomized trials demonstrated that lenalidomide maintenance after autologous stem-cell transplant significantly prolongs progression-free survival (CALGB 100104: McCarthy et al., NEJM 2012; updated Lonial et al., Blood 2022; Myeloma XI: Jackson et al., Lancet Oncology 2019). CALGB 100104 showed median PFS 46 months with maintenance vs 27 months without—a 19-month benefit. Myeloma XI confirmed both PFS and overall survival gains."

2. Emphasize that maintenance is active treatment, not prophylaxis.

"Lenalidomide in this setting is FDA-approved and NCCN category 1 recommended as treatment to delay or prevent relapse in patients who achieved response to induction/transplant. It is not 'prophylactic' in the sense of preventing an unrelated condition; it is continuation therapy targeting minimal residual disease."

3. Address MRD status if known.

"Patient achieved VGPR post-transplant but remains MRD-positive by next-generation sequencing at 10⁻⁵ sensitivity (flow or NGS report attached). MRD positivity predicts early relapse. Maintenance therapy is specifically intended to convert MRD+ to MRD− or delay progression in MRD+ patients (per CASSIOPEIA and GRIFFIN trials)."

4. Document NCCN category 1 recommendation.

"NCCN MM guidelines v.3.2024 list lenalidomide maintenance as category 1 (highest evidence level, uniform consensus) for all patients post-auto-HSCT, regardless of risk status. Your plan's coverage policy states that NCCN category 1 treatments are 'medically necessary.'"

5. Counter arbitrary duration limits.

If the insurer approves maintenance but caps it at 1 or 2 years: "CALGB 100104 and Myeloma XI continued maintenance until progression or intolerance, with no prespecified duration cap. Median duration in CALGB 100104 was ~30 months, and many patients continued >5 years. Stopping arbitrarily at 2 years contradicts the trial design and denies the patient the proven survival benefit."

6. Offer compromise on dose/schedule if toxicity is cited.

If the insurer flags cost or toxicity concerns: "Patient tolerates lenalidomide 10 mg daily (or 15 mg 21/28 days) with manageable side effects. Oncologist monitors CBC and adjusts dose per label. We request approval to continue at the current effective dose rather than forcing dose reduction that may compromise efficacy. If cost is a concern, we note that generic lenalidomide is now available, reducing per-cycle cost significantly."

---

What We Do

We specialize in overturning insurance denials for cancer patients, including complex multiple myeloma cases involving novel bispecifics, subcutaneous formulations, high-cost maintenance regimens, and disputed line-of-therapy counts. Our team works directly with your oncologist to gather the clinical documentation—FISH cytogenetics, MRD reports, imaging showing progression, trial-by-trial treatment history—that transforms a template denial into a winnable appeal. We draft peer-to-peer prep sheets, write exhaustive appeals citing every applicable trial and guideline, and escalate to external review or state insurance regulators when necessary. If you have been denied coverage for Tecvayli, Darzalex Faspro, Revlimid maintenance, or any other multiple myeloma therapy, we can help you fight back with evidence and persistence.

---

Sources

1. Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology 2016;17:e328–e346.

2. Moreau P, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine 2022;387:495–505. (MajesTEC-1)

3. Mateos M-V, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematology 2020;7:e370–e380.

4. Facon T, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. New England Journal of Medicine 2019;380:2104–2115. (MAIA)

5. Mateos M-V, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. New England Journal of Medicine 2018;378:518–528. (ALCYONE)

6. Attal M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019;394:2096–2107.

7. McCarthy PL, et al. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine 2012;366:1770–1781. (CALGB 100104)

8. Lonial S, et al. Randomized Trial of Lenalidomide Versus Observation as Maintenance Therapy in Patients With Multiple Myeloma After Autologous Stem Cell Transplantation. Blood 2022;140(Suppl 1):2059–2060. (CALGB 100104 long-term follow-up)

9. Jackson GH, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology 2019;20:57–73.

10. Durie BGM, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017;389:519–527.

11. Moreau P, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019;394:29–38.

12. Voorhees PM, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136:936–945.

13. Gay F, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncology 2021;22:1705–1720.

14. Grosicki S, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 2020;396:1563–1573.

15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma, version 3.2024. Available at NCCN.org (institutional access required).

16. U.S. Food and Drug Administration. Prescribing Information for Tecvayli (teclistamab-cqyv), Darzalex Faspro (daratumumab and hyaluronidase-fihj), Sarclisa (isatuximab-irfc), Elrexfio (elranatamab-bcmm), Talvey (talquetamab-tgvs), Lynozyfic (linvoseltamab-gcpt). Accessible via www.accessdata.fda.gov/scripts/cder/daf.

17. American Society of Hematology / American Society of Clinical Oncology. Clinical practice guidelines and annual meeting abstracts on multiple myeloma management (various years, 2012–2024).

---

Disclaimer: This guide is educational and not a substitute for individualized legal or medical advice. Insurance appeals are fact-specific; outcomes depend on your plan documents, state law, clinical details, and the strength of documentation. Consult with your oncologist and, if needed, a health advocate or attorney experienced in insurance appeals.